TRIUMPH program trial design overview — all Phase 3 arms

BiostatsBrad said:

For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.

Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.

BiostatsBrad said:

For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.

No disagreement, though it depends on where somebody is starting from, and this thread has been assuming a starting point nobody stated.

Happy to go further on any of that.

BiostatsBrad said:

For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.

Saving this. It is the first explanation that did not require me to already understand it. Sending this to two other people who asked me the same thing last week.

Adding the clinical framing, because it changes how the question reads. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

Closing the loop on my own question.

Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.